Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Some of the hottest opportunities can be found in biotech stocks to buy now. With innovation, mergers and acquisitions, major companies looking to replenish their pipelines ahead of patent expirations, treatments for obesity, aging baby boomers, and demand for better care are creating massive opportunities. We’re even seeing big opportunities in cancer treatments known as ADCs (antibody-drug conjugates), and in gene-editing. We can even look at the impact artificial intelligence could have on he